Back

Electrocardiographic evaluation of depolarization and repolarization abnormalities in breast cancer patients with HER2-inhibitor related cardiac dysfunction

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Pharmacology and Pharmacotherapy ePosters Cardiotoxicity of Drugs ESC Premium Access ESC Congress 2020

About the speaker

Photo
Assistant Professor Toshio Kinoshita

Toho University, Tokyo (Japan)

56 More presentations in this session

Presentation thumbnail
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Professor Y. Huo (Beijing, CN)
Abstract Slides
Presentation thumbnail
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
Doctor C. Becker (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics
Doctor S. Frechen (Leverkusen, DE)
Abstract Slides
Presentation thumbnail
Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study
Doctor C. Ballantyne (Houston, US)
Abstract Slides
Presentation thumbnail
The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population
Doctor D. Radenkovic (Greater London, GB)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology and Pharmacotherapy ePosters

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Can we accurately predict cardiovascular complications in targeted cancer therapies?
thumbnail
Webinar
Multidisciplinary strategies for monitoring and managing cardiovascular toxicity in patients with cancer
thumbnail
Congress Presentation
Treatment options for cancer therapy-related cardiac dysfunction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources